Apollo Endosurgery (Apollo Endosurgery) Deferred Tax : $0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Apollo Endosurgery Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Apollo Endosurgery's change in deferred tax for the three months ended in Dec. 2022 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

Apollo Endosurgery Deferred Tax Historical Data

The historical data trend for Apollo Endosurgery's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollo Endosurgery Deferred Tax Chart

Apollo Endosurgery Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Deferred Tax

Get a 7-Day Free Trial

Apollo Endosurgery Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Apollo Endosurgery Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Apollo Endosurgery Deferred Tax Related Terms

Thank you for viewing the detailed overview of Apollo Endosurgery's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollo Endosurgery (Apollo Endosurgery) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apollo Endosurgery Inc (NAS:APEN) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

N/A

Address

1120 S. Capital of Texas Highway, Building 1, Suite 300, Austin, TX, USA, 78746

Website

https://www.apolloendo.com

Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focuses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include the OverStitch Endoscopic Suturing System, X-Tack Endoscopic HeliX Tacking System, and the Orbera Intragastric Balloon System.

Executives

Antal Rohit Desai	10 percent owner	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Sharon O'keefe	director	C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Jeannette Bankes	director	ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffrey G. Black	officer: Chief Financial Officer	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Mike Gutteridge	officer: VP, Int'l Sales and Marketing	1120 S. CAPITAL OF TEXAS HIGHWAY, BUILDING 1, SUITE #300, AUSTIN TX 78746
Cpmg Inc	10 percent owner	4215 WEST LOVERS LANE, SUITE 100, DALLAS TX 75209
Mcgaughy R Kent Jr	director, 10 percent owner	500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Chas Mckhann	director, officer: President and CEO	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Pacitti	director	C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
John R Barr	director	VI TECHNOLOGIES INC, 134 COOLIDGE AVENUE, WATERTOWN MA 02472
Neil Gagnon	10 percent owner	1370 AVENUE OF THE AMERICAS, 24TH FLOOR, NEW YORK NY 10019
Traweek James W Jr	10 percent owner	2000 MCKINNEY AVE, SUITE 2125, DALLAS TX 75201
Todd Newton	director, officer: Chief Executive Officer	1120 S CAPITAL OF TX HWY, BUILDING ONE, STE 300, AUSTIN TX 78746
Stonepine Capital, L.p.	10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Matthew S Crawford	director, 10 percent owner	3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746